SUMO-interacting motifs of human TRIM5α are important for antiviral activity

PLoS Pathogens

Volumn 7, Issue 4, 2011, Pages

  Arriagada, Gloria ^a,b   Muntean, Lucia N ^a   Goff, Stephen P ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMO 1 PROTEIN; TRIPARTITE MOTIF PROTEIN 5; CARRIER PROTEIN; SMALL INTERFERING RNA; SUMO1 PROTEIN, HUMAN; TRIM5 PROTEIN, HUMAN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION; SEQUENCE ANALYSIS; VIRUS INHIBITION; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MOLONEY LEUKEMIA ONCOVIRUS; PATHOGENICITY; PROTEIN MOTIF; STRUCTURAL GENE; SUMOYLATION; VIRUS CAPSID;

MURINE LEUKEMIA VIRUS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CAPSID; CARRIER PROTEINS; CELL LINE; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; GENES, GAG; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; RNA, SMALL INTERFERING; SUMO-1 PROTEIN; SUMOYLATION;

EID: 79955752142     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002019     Document Type: Article

References (87)

1. Wolf D, Goff SP, (2008) Host restriction factors blocking retroviral replication. Annu Rev Genet 42: 143-163.
2. Lilly F, (1967) Susceptibility to two strains of Friend leukemia virus in mice. Science 155: 461-462.
3. Best S, Le Tissier P, Towers G, Stoye JP, (1996) Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829.
4. Hartley JW, Rowe WP, Huebner RJ, (1970) Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. J Virol 5: 221-225.
5. Hopkins N, Schindler J, Hynes R, (1977) Six-NB-tropic murine leukemia viruses derived from a B-tropic virus of BALB/c have altered p30. J Virol 21: 309-318.
6. DesGroseillers L, Jolicoeur P, (1983) Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J Virol 48: 685-696.
7. Kozak CA, Chakraborti A, (1996) Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 225: 300-305.
8. Rowe WP, (1972) Studies of genetic transmission of murine leukemia virus by AKR mice. I. Crosses with Fv-1 n strains of mice. J Exp Med 136: 1272-1285.
9. Jolicoeur P, Baltimore D, (1976) Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. Proc Natl Acad Sci U S A 73: 2236-2240.
10. Boone LR, Innes CL, Heitman CK, (1990) Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J Virol 64: 3376-3381.
11. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
12. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD, (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 101: 10774-10779.
13. Keckesova Z, Ylinen LM, Towers GJ, (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101: 10780-10785.
14. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, et al. (2004) TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A 101: 11827-11832.
15. Yap MW, Nisole S, Lynch C, Stoye JP, (2004) Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101: 10786-10791.
16. Besnier C, Takeuchi Y, Towers G, (2002) Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 99: 11920-11925.
17. Besnier C, Ylinen L, Strange B, Lister A, Takeuchi Y, et al. (2003) Characterization of murine leukemia virus restriction in mammals. J Virol 77: 13403-13406.
18. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, et al. (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 99: 11914-11919.
19. Himathongkham S, Luciw PA, (1996) Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology 219: 485-488.
20. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, et al. (2000) A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 97: 12295-12299.
21. Yap MW, Nisole S, Stoye JP, (2005) A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15: 73-78.
22. Nisole S, Stoye JP, Saib A, (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799-808.
23. Nakayama EE, Miyoshi H, Nagai Y, Shioda T, (2005) A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 79: 8870-8877.
24. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD, (2005) Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 79: 15567-15572.
25. Sebastian S, Luban J, (2005) TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2: 40.
26. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103: 5514-5519.
27. Stremlau M, Perron M, Welikala S, Sodroski J, (2005) Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145.
28. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, et al. (2006) Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349: 300-315.
29. Massiah MA, Matts JA, Short KM, Simmons BN, Singireddy S, et al. (2007) Solution structure of the MID1 B-box2 CHC(D/C)C(2)H(2) zinc-binding domain: insights into an evolutionarily conserved RING fold. J Mol Biol 369: 1-10.
30. Berthoux L, Sebastian S, Sayah DM, Luban J, (2005) Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 79: 7883-7888.
31. Mische CC, Javanbakht H, Song B, Diaz-Griffero F, Stremlau M, et al. (2005) Retroviral restriction factor TRIM5alpha is a trimer. J Virol 79: 14446-14450.
32. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD, (2005) Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 79: 8969-8978.
33. Hay RT, (2005) SUMO: a history of modification. Mol Cell 18: 1-12.
34. Geiss-Friedlander R, Melchior F, (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956.
35. Desterro JM, Thomson J, Hay RT, (1997) Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett 417: 297-300.
36. Schwarz SE, Matuschewski K, Liakopoulos D, Scheffner M, Jentsch S, (1998) The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc Natl Acad Sci U S A 95: 560-564.
37. Hochstrasser M, (2001) SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107: 5-8.
38. Jackson PK, (2001) A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15: 3053-3058.
39. Verger A, Perdomo J, Crossley M, (2003) Modification with SUMO. A role in transcriptional regulation. EMBO Rep 4: 137-142.
40. Saitoh H, Hinchey J, (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252-6258.
41. Rosas-Acosta G, Russell WK, Deyrieux A, Russell DH, Wilson VG, (2005) A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol Cell Proteomics 4: 56-72.
42. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, et al. (2006) Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 5: 2298-2310.
43. Minty A, Dumont X, Kaghad M, Caput D, (2000) Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275: 36316-36323.
44. Sampson DA, Wang M, Matunis MJ, (2001) The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem 276: 21664-21669.
45. Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, et al. (2005) Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280: 4102-4110.
46. Song J, Zhang Z, Hu W, Chen Y, (2005) Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280: 40122-40129.
47. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I, (2006) Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 281: 16117-16127.
48. Boggio R, Chiocca S, (2006) Viruses and sumoylation: recent highlights. Curr Opin Microbiol 9: 430-436.
49. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S, (2004) A mechanism for inhibiting the SUMO pathway. Mol Cell 16: 549-561.
50. Parkinson J, Everett RD, (2000) Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J Virol 74: 10006-10017.
51. Lamsoul I, Lodewick J, Lebrun S, Brasseur R, Burny A, et al. (2005) Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol Cell Biol 25: 10391-10406.
52. Gurer C, Berthoux L, Luban J, (2005) Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol 79: 910-917.
53. Weldon RA Jr, Sarkar P, Brown SM, Weldon SK, (2003) Mason-Pfizer monkey virus Gag proteins interact with the human sumo conjugating enzyme, hUbc9. Virology 314: 62-73.
54. Yueh A, Leung J, Bhattacharyya S, Perrone LA, de los Santos K, et al. (2006) Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection. J Virol 80: 342-352.
55. Aagaard L, Mikkelsen JG, Warming S, Duch M, Pedersen FS, (2002) Fv1-like restriction of N-tropic replication-competent murine leukaemia viruses in mCAT-1-expressing human cells. J Gen Virol 83: 439-442.
56. Towers G, Collins M, Takeuchi Y, (2002) Abrogation of Ref1 retrovirus restriction in human cells. J Virol 76: 2548-2550.
57. Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A, (1995) Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol 76(Pt 11): 2723-2730.
58. Sebastian S, Grutter C, Strambio de Castillia C, Pertel T, Olivari S, et al. (2009) An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding. J Virol 83: 3365-3373.
59. Song B, Diaz-Griffero F, Park DH, Rogers T, Stremlau M, et al. (2005) TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology 343: 201-211.
60. Campbell EM, Dodding MP, Yap MW, Wu X, Gallois-Montbrun S, et al. (2007) TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell 18: 2102-2111.
61. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, et al. (2006) Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 80: 9754-9760.
62. Song B, Gold B, O'Huigin C, Javanbakht H, Li X, et al. (2005) The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol 79: 6111-6121.
63. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, et al. (2005) Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 79: 3930-3937.
64. Shi J, Aiken C, (2006) Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 350: 493-500.
65. Ylinen LM, Keckesova Z, Webb BL, Gifford RJ, Smith TP, et al. (2006) Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol 80: 7332-7338.
66. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J, (2005) The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem 280: 26933-26940.
67. Li X, Gold B, O'HUigin C, Diaz-Griffero F, Song B, et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360: 419-433.
68. Li X, Li Y, Stremlau M, Yuan W, Song B, et al. (2006) Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J Virol 80: 6198-6206.
69. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, et al. (2007) The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 81: 2138-2148.
70. Diaz-Griffero F, Kar A, Perron M, Xiang SH, Javanbakht H, et al. (2007) Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol 81: 10362-10378.
71. Yamauchi K, Wada K, Tanji K, Tanaka M, Kamitani T, (2008) Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J 275: 1540-1555.
72. Prudden J, Pebernard S, Raffa G, Slavin DA, Perry JJ, et al. (2007) SUMO-targeted ubiquitin ligases in genome stability. EMBO J 26: 4089-4101.
73. Uzunova K, Gottsche K, Miteva M, Weisshaar SR, Glanemann C, et al. (2007) Ubiquitin-dependent proteolytic control of SUMO conjugates. J Biol Chem 282: 34167-34175.
74. Geoffroy MC, Hay RT, (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 10: 564-568.
75. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The tripartite motif family identifies cell compartments. EMBO J 20: 2140-2151.
76. Tavalai N, Stamminger T, (2008) New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta 1783: 2207-2221.
77. Matunis MJ, Zhang XD, Ellis NA, (2006) SUMO: the glue that binds. Dev Cell 11: 596-597.
78. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP, (2006) The mechanisms of PML-nuclear body formation. Mol Cell 24: 331-339.
79. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, et al. (2008) Dynamics of component exchange at PML nuclear bodies. J Cell Sci 121: 2731-2743.
80. Reichelt M, Wang L, Sommer M, Perrino J, Nour AM, et al. (2011) Entrapment of Viral Capsids in Nuclear PML Cages Is an Intrinsic Antiviral Host Defense against Varicella-Zoster Virus. PLoS Pathog 7: e1001266.
81. Campbell EM, Perez O, Anderson JL, Hope TJ, (2008) Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 180: 549-561.
82. Mortuza GB, Dodding MP, Goldstone DC, Haire LF, Stoye JP, et al. (2008) Structure of B-MLV capsid amino-terminal domain reveals key features of viral tropism, gag assembly and core formation. J Mol Biol 376: 1493-1508.
83. Bock M, Bishop KN, Towers G, Stoye JP, (2000) Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 74: 7422-7430.
84. Fu D, Collins K, (2006) Human telomerase and Cajal body ribonucleoproteins share a unique specificity of Sm protein association. Genes Dev 20: 531-536.
85. Sebastian S, Sokolskaja E, Luban J, (2006) Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol 80: 2051-2054.
86. Haedicke J, de Los Santos K, Goff SP, Naghavi MH, (2008) The Ezrin-radixin-moesin family member ezrin regulates stable microtubule formation and retroviral infection. J Virol 82: 4665-4670.
87. Arriagada G, Paredes R, van Wijnen AJ, Lian JB, van Zundert B, et al. (2010) 1alpha,25-dihydroxy vitamin D(3) induces nuclear matrix association of the 1alpha,25-dihydroxy vitamin D(3) receptor in osteoblasts independently of its ability to bind DNA. J Cell Physiol 222: 336-346.